World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
68
Citations
15227
World Ranking
2608
National Ranking
1245

Kwong Y. Tsang publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kwong Y. Tsang sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 262 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Kwong Y. Tsang D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kwong Y. Tsang sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 68 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Kwong Y. Tsang is affiliated with the National Institutes of Health in the United States. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on radiology and molecular biology subfields including oncology, immunology, and organic chemistry.

Their work mainly revolves around topics such as monoclonal and polyclonal antibodies research, glycosylation and glycoproteins research, immunotherapy and immune responses, radiopharmaceutical chemistry and applications, cancer treatment and pharmacology, and cancer immunotherapy and biomarkers.

Frequent coauthors who have collaborated with Tsang include:

  • Philip M. Arlen
  • Massimo Fantini
  • Christina M. Annunziata
  • Sharon Mavroukakis
  • Anjum Zaki

Tsang has published extensively in several venues, with a particular concentration in:

  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Journal of Clinical Oncology
  • Journal of Experimental & Clinical Cancer Research
  • Cancers

Among recent notable publications are:

  • "Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy," 2023, Frontiers in Immunology
  • "First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors," 2023, Journal of Experimental & Clinical Cancer Research
  • "The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway," 2020, Cancer Biotherapy and Radiopharmaceuticals
  • "Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas," 2022, Cancers
  • "Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer," 2020, Clinical Cancer Research

Tsang's research contributions include the development and characterization of monoclonal antibodies for cancer treatment and the study of immune responses related to cancer immunotherapy. Their investigations often intersect with studies involving radiopharmaceutical chemistry applications and molecular mechanisms underlying antibody-based therapies.

Best Publications

  • Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

    Tsang Ky;Zaremba S;Nieroda Ca;Zhu Mz

  • Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

    Charlie T. Garnett;Claudia Palena;Mala Chakarborty;Kwong-Yok Tsang

  • Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

    Benjamin Boyerinas;Caroline Jochems;Massimo Fantini;Christopher R. Heery

  • Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

    John L. Marshall;Robert J. Hoyer;Mary Ann Toomey;Kristen Faraguna

  • Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

    James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  • A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

    Joseph Paul Eder;Philip W. Kantoff;Kristin Roper;GuangXian Xu

  • Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

    John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  • Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

    Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  • Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.

    Heidi Hörig;David S. Lee;William Conkright;Joe Divito

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

    Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa

  • In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

    Pierpaolo Correale;Konstantin Walmsley;Carol Nieroda;Sam Zaremba

  • Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

    James W. Hodge;Charlie T. Garnett;Benedetto Farsaci;Claudia Palena

  • Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.

    John L. Marshall;Michael J. Hawkins;Kwong Y. Tsang;Ellen Richmond

  • Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

    James Gulley;Alice P. Chen;William Dahut;Philip M. Arlen

  • Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

    James L. Gulley;Philip M. Arlen;Kwong-Yok Tsang;Junko Yokokawa

  • The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma

    M von Mehren;P Arlen;J Gulley;A Rogatko

  • Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

    Pierpaolo Correale;Maria Saveria Rotundo;Maria Teresa Del Vecchio;Cinzia Remondo

  • Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

    Junko Yokokawa;Vittore Cereda;Cinzia Remondo;James L. Gulley

  • Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

Frequent Co-Authors

Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Massimo Fantini
Massimo Fantini Precision Biologics
James W. Hodge
James W. Hodge National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
John W. Greiner
John W. Greiner National Institutes of Health
Dennis Panicali
Dennis Panicali Harvard University
Ira Pastan
Ira Pastan Center for Cancer Research
Raymond P. Donnelly
Raymond P. Donnelly US Food and Drug Administration

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career prospects. Many students pursue nursing pathways to complement their immunology knowledge, especially through programs designed for non-traditional entrants. For example, online RN programs for non nurses offer flexible options for individuals without prior nursing experience, allowing them to transition smoothly into the healthcare field.

Accelerated nursing programs also provide fast-tracked routes to licensure. If you have a degree in a related science, enrolling in the easiest ABSN programs to get into might be an effective path, combining speed and accessibility.

For those preferring hands-on patient care with shorter training periods, easy admission LPN programs offer a straightforward entry into nursing, often paving the way for further education.

Advanced practice roles are also valuable for immunology professionals, and the easiest nurse practitioner degree programs can be a practical choice to obtain specialized credentials while managing admission hurdles.

Best Scientists Citing Kwong Y. Tsang

Trending Scientists

Recently Published Articles